TrialInfluenza and other respiratory viruses2024

Immunogenicity and Safety of AS03-Adjuvanted H7N9 Influenza Vaccine in Adults (18-64 and ≥65 Years): A Phase 1/2, Randomized, Placebo-Controlled Trial.

Andrew Hastie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.